Contact
searchSearch
HMP Global
Login

Diffuse Large B-Cell Lymphoma (ASH 2022) Basic Listing

Updates in Diffuse Large B-Cell Lymphoma
From the ASH Annual Meeting & Exposition

Conference Coverage
Retreatment With R-CHOP-Like Therapy Effective in Late-Relapse DLBCL
12/07/2024
In patients with late-relapse DLBCL, a retreatment strategy with R-CHOP-like therapy is a reasonable option and results in durable remission in a high proportion of patients, according to a retrospective study presented at the 2024 ASH Annual...
In patients with late-relapse DLBCL, a retreatment strategy with R-CHOP-like therapy is a reasonable option and results in durable remission in a high proportion of patients, according to a retrospective study presented at the 2024 ASH Annual...
In patients with late-relapse...
12/07/2024
Oncology
Conference Coverage
Real-World Efficacy of Bispecific Antibodies for Patients With Relapsed or Refractory Large B-Cell Lymphomas
12/05/2024
According to results from a retrospective study presented at the 2024 ASH Annual Meeting & Exposition, the bispecific antibodies epcoritamab and glofitamab demonstrated worse outcomes among patients with relapsed or refractory large b-cell...
According to results from a retrospective study presented at the 2024 ASH Annual Meeting & Exposition, the bispecific antibodies epcoritamab and glofitamab demonstrated worse outcomes among patients with relapsed or refractory large b-cell...
According to results from a...
12/05/2024
Oncology
Conference Coverage
Time of CAR-T Cell Therapy Failure May Predict Outcomes of Bispecific Antibody Therapy Among Patients With Relapsed or Refractory Large B-Cell Lymphoma
12/05/2024
According to a retrospective, real-world study presented at the 2024 ASH Annual Meeting & Exposition, the timing of CAR-T cell therapy failure may predict the outcomes for bispecific antibody therapies for patients with relapsed/refractory...
According to a retrospective, real-world study presented at the 2024 ASH Annual Meeting & Exposition, the timing of CAR-T cell therapy failure may predict the outcomes for bispecific antibody therapies for patients with relapsed/refractory...
According to a retrospective,...
12/05/2024
Oncology
Conference Coverage
CD22-Directed CAR-T Therapy Provides Durable Remission and Long-Term Survival in Large B-Cell Lymphoma
12/05/2024
Among patients with large B-cell lymphoma progressing after CD19-directed CAR T-cell therapy, treatment with CD22-Directed CAR T-cells provided durable remissions and long-term survival after 3 years, according to follow-up data presented at...
Among patients with large B-cell lymphoma progressing after CD19-directed CAR T-cell therapy, treatment with CD22-Directed CAR T-cells provided durable remissions and long-term survival after 3 years, according to follow-up data presented at...
Among patients with large B-cell...
12/05/2024
Oncology
Oluwatobi Odetola, MD,
Conference Coverage
Promising Efficacy of Frontline Nivolumab in Combination With R-CHOP for Patients With High-Risk DLBCL
12/12/2023
During the 2023 ASH Annual Meeting in San Diego, Oluwatobi Odetola, MD, shared data from a phase 1b study that evaluated the safety and efficacy of nivolumab in combination with R-CHOP in high-risk DLBCL.
During the 2023 ASH Annual Meeting in San Diego, Oluwatobi Odetola, MD, shared data from a phase 1b study that evaluated the safety and efficacy of nivolumab in combination with R-CHOP in high-risk DLBCL.
During the 2023 ASH Annual...
12/12/2023
Oncology
Martin Hutchings, MD, PhD, Rigshospitalet, Copenhagen
Videos
Glofitamab Plus Polatuzumab Vedotin Shows Frequent, Durable Responses and Manageable Safety Among Patients With R/R DLBCL
12/12/2023
At the 65th ASH Annual Meeting, Martin Hutchings, MD, discussed updated data on the combination of glofitamab plus polatuzumab vedotin, which yielded high response rates and manageable safety among heavily pretreated patients with diffuse...
At the 65th ASH Annual Meeting, Martin Hutchings, MD, discussed updated data on the combination of glofitamab plus polatuzumab vedotin, which yielded high response rates and manageable safety among heavily pretreated patients with diffuse...
At the 65th ASH Annual Meeting,...
12/12/2023
Oncology
Narendranath Epperla, MD, MS
Conference Coverage
Analyzing Outcomes of Tafasitamab for the Treatment of R/R DLBCL Among Racial and Ethnic Minorities
12/11/2023
At the 2023 ASH Annual Meeting, Narendranath Epperla, MD, MS, presented a retrospective cohort study analyzing the patterns and outcomes of treatment with tafasitamab among patients with R/R diffuse large B-cell lymphoma across racial and...
At the 2023 ASH Annual Meeting, Narendranath Epperla, MD, MS, presented a retrospective cohort study analyzing the patterns and outcomes of treatment with tafasitamab among patients with R/R diffuse large B-cell lymphoma across racial and...
At the 2023 ASH Annual Meeting,...
12/11/2023
Oncology
Conference Coverage
R-CHOP Plus Tazemetostat Therapy Feasible Among Older Patients With Newly Diagnosed DLBCL
12/11/2023
Efficacy results of the phase 2 TAZ R-CHOP study demonstrate that R-CHOP plus tazemetostat is a feasible treatment option among older patients with newly diagnosed diffuse large B-cell lymphoma.
Efficacy results of the phase 2 TAZ R-CHOP study demonstrate that R-CHOP plus tazemetostat is a feasible treatment option among older patients with newly diagnosed diffuse large B-cell lymphoma.
Efficacy results of the phase 2...
12/11/2023
Oncology
Conference Coverage
Odronextamab Monotherapy Shows Promising Antitumor Activity Among Patients With R/R DLBCL Post CAR T-Cell Therapy
12/11/2023
Odronextamab monotherapy demonstrated encouraging antitumor activity and generally manageable safety among heavily pretreated patients with DLBCL who have progressed after CAR T-cell therapy, according to a phase 1 study.
Odronextamab monotherapy demonstrated encouraging antitumor activity and generally manageable safety among heavily pretreated patients with DLBCL who have progressed after CAR T-cell therapy, according to a phase 1 study.
Odronextamab monotherapy...
12/11/2023
Oncology
Charalambos Andreadis, MD 
Conference Coverage
Ibrutinib With Standard Conditioning and as Consolidation Therapy Following AutoHCT Well-Tolerated Among Patients With DLBCL
12/10/2023
At the 65th ASH Annual Meeting, Charalambos Andreadis, MD, presented on a phase 3 trial evaluating the efficacy of the addition of ibrutinib to autoHCT as conditioning and as consolidation therapy for patients with R/R ABC diffuse large...
At the 65th ASH Annual Meeting, Charalambos Andreadis, MD, presented on a phase 3 trial evaluating the efficacy of the addition of ibrutinib to autoHCT as conditioning and as consolidation therapy for patients with R/R ABC diffuse large...
At the 65th ASH Annual Meeting,...
12/10/2023
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use